PIH34 A Systematic Review of Patient Preferences for Subcutaneous Medications  by Ridyard, C. et al.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A335
were asked to complete Accept and MMAS-4 questionnaires at Month 1, 3 and 
6 after having given their informed consent. The structure was explored through 
PCA, and confirmed with multi-trait analysis. Internal consistency reliability 
of dimensions was assessed through Cronbach’s alpha. Scale-scale correla-
tions were calculated. Results: After reduction, Accept was made of 25 items 
organised in 1 overall Acceptance score and 6 domain-specific scores (efficacy, 
tolerance, convenience, constraints, treatment duration, multiple medica-
tion). Cronbach’s alpha was 0,85 for overall Acceptance score, which met con-
vergent and divergent validity criteria (both 100%). The domain-specific scores 
showed satisfactory to good results (Cronbach’s alpha ranging from 0,67 - 0,87, 
convegrent validity ranging from 63% to 100%, and divergent validity ranging 
from 33% - 100%). Scale-scale correlations ranged from 0.02 to 0.58, confirming the 
multi-dimensional nature of the questionnaire. The good properties of Accept were 
stable over time. ConClusions: Accept is a brief, comprehensive, generic ques-
tionnaire focused on Acceptance. Initial validation in a population of patients with 
a wide range of long-term treatment showed promising results and confirmed 
the position of Acceptance. Further, disease-specific, large prospective study are 
needed to assess the ability of Accept to predict persistence to treatment.
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objeCtives: Implementation of co-payments may reduce the use of essential medi-
cations, worsen patients’ outcomes, and increase overall health care costs. The aim 
of this study was to examine to what extent non-adherence of chronic patients to 
medication stems from financial reasons and what determinants are associated with 
non-adherence. Methods: A telephone survey was conducted among a representa-
tive sample of Maccabi Healthcare Services chronic patients aged ≥ 55 yrs (n= 522). 
Respondents were defined as non-adherent if they reported they had stopped tak-
ing prescribed medications in the previous year and/or not purchasing prescribed 
medications due to its cost. Additional information collected included: age, gender, 
income, receiving explanation from a physician regarding the therapy, and out-of-
pocket expenditure for prescribed medications. Results: Mean age of the study 
population was 69.9±9.0 yrs (53% were male). Sixteen percent of respondents were 
defined as non-adherent, in 60% of them it was due to medication’s cost. No sig-
nificant differences were found between adherent and non-adherent respondents 
with regard to: age, gender, family status, country of birth, supplementary insurance 
coverage, or education. In a multivariable logistic regression model, non-adherence 
was associated with: lack of physician explanation about prescribed medications 
(OR= 2.88, 95%CI: 1.46-5.68, P= 0.002); higher out-of-pocket expenditure on medications 
(OR= 1.93, 95%CI: 1.04-3.61, P= 0.04), and lower household income (OR= 0.81, 95%CI: 
0.69-0.96, P= 0.01). ConClusions: Information provided by physicians is associated 
with adherence of chronic patients to prescribed medications. Low income and high 
out-of-pocket expenditure for prescribed medication are associated with non-adher-
ence. Since adherence is strongly affected even by a relatively low and flat co-payment 
as applied in Maccabi Healthcare Services, health policy makers may consider adop-
tion of value-based co-payments that are differentiated by treatment value rather 
than by its cost, and targeted mainly at chronic patients. This approach may lead to 
improved adherence and outcomes with the potential of reducing long-term costs.
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objeCtives: In light of the presumed costs of non-adherence to medication and the 
pressure to reduce unnecessary health care expenditures in the current economic 
climate, a review that assesses evidence of cost-effectiveness of adherence enhancing 
interventions would be timely. The objective of this paper is to examine the cost-
effectiveness of adherence enhancing interventions and the quality of the studies 
reviewed. Methods: MEDLINE, PsycInfo, EconLit and the Centre for Reviews and 
Dissemination databases were searched for randomised controlled trials that per-
formed full economic evaluations of adherence enhancing interventions. Information 
was collected on study characteristics, cost-effectiveness of treatment alternatives, 
quality of economic evaluations, and risk of bias. Results: Fourteen studies were 
included, of which the overall quality was found to be moderate. Five used a societal 
perspective, eight a provider perspective, and a single study used a patient perspec-
tive. Ten studies examined interventions that were both more costly and more effec-
tive than usual care, and four were less costly and more effective. Comprehensive 
evidence from the societal perspective yielded disappointing results for potential 
cost-effectiveness of adherence interventions. Studies from other perspectives pro-
vided weak to moderately promising evidence that adherence interventions can 
be cost-effective. ConClusions: Few randomised controlled trials examined the 
cost-effectiveness of adherence interventions. There was limited evidence of poten-
tial cost-effectiveness of adherence programmes. Most interventions did not report 
whether their intervention was effective in the first place, and many suffered from 
methodological limitations. To demonstrate that adherence interventions offer soci-
etal benefits, we recommend that the most promising interventions are subjected to 
a rigorous cost-effectiveness evaluation.
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and 97.87% respectively. ConClusions: This analysis portends dienogest as a cost-
saving alternative for the treatment of EAPP compared to GnRHa in Brazil from the 
public and private payer perspective.
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objeCtives: In England, nearly two-thirds of older people in acute hospital care 
suffer from co-morbid physical and mental health conditions. This study inves-
tigated the health and social care costs for a group of older (70+) people iden-
tified with a mental health condition after hospital admission. Methods: The 
Better Mental Health (BMH) study recruited 247 patients at hospital admission in 
Nottingham, England. Electronic administrative records were sought for six months 
post-admission from health (services: general practices, hospitals, ambulance trans-
port, intermediate and mental health care) and social care. The cohort was charac-
terised by one or more aspects of mental health: cognitive impairment, depression, 
delirium, and neuropsychiatric health. Differences in mean cost between groups 
were assessed using t-tests; association between mental health and service-level 
cost was investigated using GLM regression. Results: Health and social care costs 
were derived for all 247 participants, except primary care, derived for 122 (subset) 
participants due to GP recruitment. In the subset, mean (95% CI, median, range) total 
cost was £9842 (8573-11256, 7717, 715-48795). Mean cost (95% CI) for mental health 
care was significantly (p< 0.05) higher for patients: with depression than without 
(£194 (106-322) Vs. £55 (17-111)); bottom-50% on the neuropsychiatric health scale 
(£202 (124-298) Vs. £55 (16-118)). Patients with delirium, compared to without, had 
significantly lower costs for GP consultations (£316 (196-492) Vs. £552 (429-701)) 
and hospital outpatient visits (£333 (253-444) Vs. £497 (400-621)). The GLM did not 
identify a significant association between aspects of mental health and service-
level costs. ConClusions: This study suggests a person’s mental health affects 
consumption of some, but not all, services evaluated. In general, these patients are 
costly, high resource-users, of health and social care services; however, this con-
sumption pattern cannot be attributed to one particular aspect of mental health. 
Future work should investigate the impact of physical and mental health comor-
bidities on resource-use.
InDIvIDual’s HealtH – Patient-reported outcomes & Patient Preference studies
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objeCtives: To determine the association between medication adherence and 
adverse drug events (ADEs), health related quality of life (HRQOL) and hospitalisa-
tion in older community dwelling patients. Methods: A retrospective cohort study 
of 855 patients aged ≥ 70 years from 15 general practices in Ireland in 2010. Medication 
adherence was measured by: (i) the Medication Possession Ratio (MPR) using national 
pharmacy claims dispensing data; and (ii) self-report using the Morisky Medication 
Adherence Scale. ADEs and hospitalisation were measured by patient medical record 
and self-report for the previous 6 months. ADEs were reviewed by two independent 
clinicians. HRQOL was measured using EQ-5D. Multilevel Poisson and linear regression 
were used to examine how the number of ADEs, utility and hospitalisation varied by 
adherence after adjusting for patient and practice level covariates; socioeconomic 
status, deprivation, co-morbidity, number of drugs, functional disabilities, social sup-
port and health insurance. Results: A total of 592 (69%) patients were adherent 
based on dispensed pharmacy claims data (MPR ≥ 80%) and 553 (63%) self-reported 
adherence to their medication. The median MPR for self-reported adherent patients 
was 0.88 (IQR: 0.78, 0.95) compared to 0.86 (IQR: 0.71, 0.93) for non-adherent patients 
(p< 0.01). Non-adherence (MPR< 80%) was not significantly associated with any ADEs 
but self-reported non-adherent patients had an increased risk of any ADEs (IRR 1.18; 
95% CI 1.05, 0, 1.33 p< 0.01). Non-adherent patients had a significantly lower mean 
HRQOL utility (MPR coefficient, -0.11, SE 0.03, p< 0.001; self-report coefficient, -0.06, 
SE 0.01, p< 0.001) and an almost two-fold increased risk in the expected rate of any 
hospitalisation (MPR IRR, 1.75; 95% CI, 1.42, 2.15, p< 0.001; self-report IRR, 1.53; 95% CI, 
1.16, 2.01, p< 0.01) compared to adherent patients. ConClusions: Non-adherence 
was significantly associated with adverse health outcomes. Developing methods 
to assist older adults in accurate and safe management of their medications may 
increase their quality of life.
PIH31
valIDatIon of accePt, a new generIc measure to assess How PatIents 
wItH cHronIc DIseases balance between tHe aDvantages anD 
DIsaDvantages of followIng tHe recommenDeD treatment regImen 
In real-lIfe
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objeCtives: To reduce, score, and validate the Accept questionnaire. Methods: 
Accept is a 32-items PRO questionnaire measuring the concept of Acceptance. 
It was developed based on grounded theory and qualitative research. Each 
treatment characteristic was assessed on a response scale opposing “easy to 
accept” to “not easy to accept”. We conducted an observational prospective 
study on 182 subjects engaged in long-term treatment regimen. Adult patients 
where consecutively recruited by a network of pharmacists when prescribed 
with a drug indicated in various chronic diseases (including asthma, diabetes, 
various cardio-vascular diseases, retroviral infections, osteoporosis). Patients 
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prescription medications. Given the financial burden of using multiple medications, 
and the lower incomes of these patients, cost-saving methods are more frequently 
utilized by these patients.
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objeCtives: In the last 15 years our research activity collected several HRQoL data, 
through the EQ-5D-3L and other generic (SF-36) or condition-specific question-
naires. The objective was to assess and compare HRQoL among different popula-
tion subgroups. Methods: We reviewed all the HRQoL studies conducted by our 
research group between 1998 and 2012. We identified several conditions to be com-
pared in terms of VAS score and utility index: these were assessed using the Italian 
social tariffs and then adjusted for age and sex. Results: The archive included 
QoL data from 7,754 subjects (51.5% male), grouped in 29 different subgroups: type 
1 and 2 diabetes mellitus, moderate to severe haemophilia, major depression, 
atopic dermatitis, severe and chronic hand eczema, psoriatic arthritis, schizophre-
nia/schizophrenic disorder, β -thalassemia major, gastroesophageal reflux, abdomi-
nal aortic aneurysm, systemic sclerosis, chronic hepatitis B, chronic hepatitis C, 
hepatitis from other causes, cirrhosis, hepatocellular carcinoma, liver transplant, 
general Italian population aged from 18 to 75 years. Overall, the subjects were aged 
from 14 to 96 years (mean(+SD)= 55.7(+17.1), median= 57.7). The adjusted EQ-5D-
VAS mean+SD ranged from a minimum of 33.9+14.1 in patients with a major 
depression episode, to a maximum of 82.5+12.9 in patients with atopic dermatitis 
8 weeks after flare. The mean+SD VAS was 73.2+11.4 in the general population. The 
adjusted mean+SD utility index ranged from 0.60+0.17 in psoriatic arthritis before 
starting treatment with biological agents, to 0.931+0.09 among chronic hepatitis 
B patients. ConClusions: The many EQ-5D data collected in the last 15 years 
are merged now in a unique archive that can be used to assess and compare the 
burden of disease in terms of HRQoL in different subpopulations. This archive is to 
be considered preliminary and deemed to be integrated with additional data from 
ongoing or future projects, and perhaps with other analogous archives created in 
other contexts and Countires.
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objeCtives: A key dimension impacting clinical outcomes in health care evaluation 
is satisfaction (i.e. the level of meeting user’s expectations for the service), which 
impact adherence and persistence. Yet, evidence regarding patient dissatisfaction 
is scarce. Thus, we asked what the level of dissatisfaction is after a health centre 
(HC) visit, and which factors impact the dissatisfaction? Methods: A prospective 
survey to primary care patients visiting 3 Finnish HCs (Linnainmaa, Omapihlaja, 
Pirkkala) in Pirkanmaa district during 31.1–11.2.2011 was done. No inclusion/exclu-
sion criteria were used. Comprehensive patient-, clinician- and HC-related data was 
collected. The patient’s satisfaction was measured immediately after the visit in the 
form of handling problem during a visit (Likert range 0–10). This was inversed to 
assess the drawback related to the visit (0= full benefit; problem was solved; 10= no 
benefit; full drawback). An explorative statistical analysis was done including mul-
tivariate data mining in order to find the model with the best Akaike information 
criteria. The model aimed to demonstrate the independent factors impacting the 
drawback and control heterogeneity. Results: A total of 90.1% of the full sample 
(n= 647) answered to the drawback question. 40.3% of the patients had problem 
solved during the visit (i.e. reported 0) and just 6.9% of the patients experienced 
drawback exceeding 5. The factors increasing the drawback in the stepwise OLS 
regression model with the +1 ln-transformation for the drawback were longer wait-
ing time, asthma/copd and male sex. The factors decreasing the drawback were 
patient’s higher subjective health status, patient’s higher subjective health status 
in comparison to others of same age/sex, some long-term conditions (rheumatoid 
disease, allergy, hip/knee joint erosion), clinician’s longer experience, clinician in 
specialising education and certain HC. ConClusions: Some 60% of the patients 
experienced that their problem was not fully handled. Multiple factors impact the 
drawback which could be notified in the planning of HC services.
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objeCtives: The principal of QALY is sometimes referred to as “A QALY is a QALY 
is a QALY”, which means all QALYs have the same value, while QALYs may not 
fully reflect public preferences. If the use of QALYs in decision making proves 
beneficial but insufficient, what other factors should be taken into consideration 
simultaneously? Methods: We conducted a face-to-face survey using a discrete 
choice method to measure societal medical care preferences. The profiles of 
assumed patients consisted of the following four factors: (a) age (young or elderly 
patient); (b) objective of care (treatment or prevention); (c) severity of health 
state (severe or mild); and (d) past experience of receiving care (yes or no). These 
objeCtives: Of the many routes of drug administration, some are more accept-
able to patients than others; for example when a choice is presented, patients will 
usually prefer an oral over an injectable medication, all else being equal. Patient 
preference may be expressed in terms of health and non-health-related measures, 
which include: health technology-related attributes (including ergonomics, ease of 
use, convenience), behaviour (e.g. needle phobia and patients’ perceptions of treat-
ment), and adverse reactions attributable to the route of administration. Preferences 
may result in process-related (dis)utility, and be revealed as (non)adherence. 
This review aims to examine ambulatory patients’ preferences for subcutane-
ously administered, self-injectable medications, compared with other routes of 
administration for the same medicines. Methods: Ten electronic databases 
were searched for publications published between 2002 and 2012 using terms 
pertaining to methods of administration, preferences and adherence. Eligibility 
for inclusion was determined through reference to specific criteria by two inde-
pendent reviewers. Results: Of the 1,146 papers screened, 70 met the inclusion 
criteria. Studies focused mainly on methods of administration for insulin and 
treatments of paediatric growth disorders and multiple sclerosis. Pen devices were 
significantly preferred to needle & syringes administration in 11 out of 12 studies 
– particularly with respect to ergonomics, convenience and portability; however, 
preferences between autoinjectors and pen devices were less pronounced. Oral 
administration was preferred to subcutaneous administration in 6 studies (but did 
not reach statistical significance), as was inhaler therapy (favoured significantly 
in 3 out of 4 studies). ConClusions: The review identified a number of studies 
which revealed important differences in patient preference between methods and 
routes of drug delivery. Further evidence is required to support the notion that 
preference translates to better adherence.
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objeCtives: Adherence to treatment is an important issue in the management of 
chronic diseases and an indicator of patients’ ability to self-manage their condition. 
Some medical devices have been designed to help support patients’ self-management 
and adherence by including dose-memory and reminder functions. This literature review 
explored the role and impact of these devices on patients’ adherence to treatment, 
confidence and disease self-management. Methods: A search of Medline, Embase 
and PsycInfo was performed to identify articles published in English from 2003-2013, 
which studied the effect of devices with memory and/or reminder functions on treat-
ment adherence, confidence and self-management. The main attributes of the abstracts 
selected for inclusion and full-text review, were summarized. Results: The database 
searches yielded 940 abstracts. Of the 47 meeting the inclusion criteria, 32 were retained. 
The articles explored the impact of memory and/or reminder devices on treatment 
adherence, device usability and users’ (patients, health care professionals (HCPs) and 
caregivers) relationship and attitudes towards the devices. Devices with memory and/or 
reminder functions were found to improve self-reported and electronically-monitored 
treatment adherence in prophylactic medication use (e.g. contraceptives) and a range 
of chronic diseases including HIV, diabetes and asthma. Memory functions were con-
sidered valuable in disease management by patients and HCPs. Of particular value was 
that memory and/or reminder functions provided dose-history information, enhanced 
patients’ confidence with, and ability to manage their medication and condition, and 
helped reduce forgotten or incorrect medication dosing. ConClusions: The incorpora-
tion of memory functions alone and in combination with reminder features in medical 
devices can improve patient’s adherence, confidence and self-management. This can 
lead to improvements in disease control and clinical outcomes, thereby offering clini-
cal and economic value. This review highlights the importance of conducting further 
qualitative and quantitative research in this area to fully understand the value of these 
types of devices to patients and HCPs.
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objeCtives: Compliance with medications among elderly patients is particularly 
important, as the consequences may be quite serious. Results suggest that use of 
three or more medications may put a considerable burden on elderly patients and 
may affect their compliance. This analysis profiles elderly patients across 5EU by 
the number of medications currently used and their compliance related behaviors. 
Combination products were considered as one prescription medication. Methods: 
Results were taken from the 2011 5EU National Health and Wellness Survey, a 
nationally representative, self-administered survey. Respondents were adults age 
18 and over from France, Germany, Italy, Spain and UK. This analysis focuses on 
adults age > = 65. Physical and mental quality of life was measured using the SF12v2 
scale. Activity impairment was measured using the Work Productivity and Activity 
Impairment scale. Results: Out of the total sample of age > = 65 (n= 10,612), ~37% 
of elderly adults across 5EU currently use four or more prescription (Rx) medica-
tions to treat their conditions, 44% use 1-3 Rx medications, and 18% use no Rx 
medications. Activity impairment is greater among those using 4+ medications 
(38.6 vs. 22.7 vs. 16.0). Emergency room visits and hospitalizations are also higher. 
This group appears to be more proactive in engaging in cost-saving behaviors to 
alleviate some of the treatment costs in the past 6 months (30% vs 24% vs 15%) (e.g., 
asking for generic alternatives (19% vs 16% vs 8%), ever changing prescription to 
another drug (61% vs 51% vs 45%) and switching to a generic version of a prescribed 
drug (35% vs 27% vs 18%). ConClusions: Considerably higher health care costs 
and greater activity impairment can be seen among elderly patients using more 
